Descrizione del progetto
Biometria basata sugli occhi per test antidroga
Quasi 30 milioni di persone sono consumatori problematici di droghe. Il progetto PrevictDrugs, finanziato dall’UE, fornisce un dispositivo medico innovativo per l’autocontrollo continuo e volontario del consumo di droga. Questo dispositivo serve come componente aggiuntivo all’attuale offerta di sanità elettronica di Kontigo Care sviluppata per la gestione di altri disturbi della dipendenza, tra cui l’alcolismo e il gioco d’azzardo patologico. Utilizzando le fotocamere dello smartphone, i pazienti che soffrono di tossicodipendenza saranno identificati e sarà loro chiesto di registrare un video di 10 secondi dei loro occhi, in quanto l’analisi dei biomarcatori oculari fornisce risultati immediati. Il progetto si sta già preparando alla commercializzazione del prodotto.
Obiettivo
Drug addiction is a global problem; nearly 30 million illicit drug users worldwide suffer from problematic drug use. Kontigo Care AB is developing an innovative medical device – Previct Drugs - a robust, app-based, eHealth-platform for place unbound, continuous, voluntary, self-monitoring of drug use. It will constitute an add-on to Kontigo Care’s current eHealth offer developed for management of other addictive disorders (alcohol abuse and hazard gambling). Using smartphone cameras, patients suffering from drug addiction, will be identified, and asked to record a 10 s long video of their eyes. Analysis of eye biomarkers associated with pharmacodynamically induced pupil reactions (pupillometry) will yield instant results on drug use/sobriety.
Our unique, disruptive Internet of Thing (IoT)-based approach is designed to combine continuous monitoring of drug use and daily mood/cravings, with communication tools aimed at improving the impact of distance care. Real-time results become instantly available to caregivers through our cloud-based Care Portal, allowing fast interventions and correct patient prioritisation. This eHealth solution will drive healthcare digitalisation resulting in extreme cost-efficiency of out-patient treatments as well as convenience and complete privacy during drug screenings. A sophisticated AI-system will assess personal risks of relapse and transform addiction management to become proactive instead of reactive. This approach has the potential to enhance personalised therapy outcomes by ensuring that help can be provided fast to the patients who need it the most. The project objective is to prepare for commercialisation of the Previct Drugs module by determining the most efficient routes for gaining clinical and market acceptance by validating the product in clinical settings.
Campo scientifico
- medical and health scienceshealth scienceshealth care serviceseHealth
- natural sciencescomputer and information sciencesinternetinternet of things
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsoptical sensors
- natural scienceschemical sciencesorganic chemistryalcohols
- engineering and technologyelectrical engineering, electronic engineering, information engineeringinformation engineeringtelecommunicationsmobile phones
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
753 20 UPPSALA
Svezia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.